Loading
A phase 2 trial of Daunorubicin, Cytarabine and Eltrombopag in Leukaemia, run by Novartis Pharmaceuticals, completed.
A Safety and Efficacy Study of Eltrombopag in Subjects With AML is a phase 2 interventional study registered as NCT01890746 by Novartis Pharmaceuticals, with 148 participants recorded, started 2013-09-05 and reaching its primary completion in 2015-03-13. Interventions recorded: Daunorubicin, Cytarabine, Eltrombopag, Placebo. Conditions recorded: Acute Leukaemia.
Linked to the drug Eltrombopag because the registry names it among its interventions and Leukaemia among its conditions. Registry record only: no result has been read by an editor.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
148 enrolled.
Figures from the ClinicalTrials.gov results section (first posted 2016-06-14), not from a publication
SourceFigures from the ClinicalTrials.gov results section (first posted 2016-06-14), not from a publication
SourceShares Eltrombopag, Leukaemia (all types) and the tag pipeline.
Shares Daunorubicin, Cytarabine and the tag pipeline.
Shares Daunorubicin, Cytarabine, Leukaemia (all types) and the tag pipeline.
Shares Daunorubicin, Cytarabine, Leukaemia (all types) and the tag pipeline.
Shares Novartis, Leukaemia (all types) and the tag pipeline.
Shares Daunorubicin, Cytarabine, Novartis and the tag pipeline.
Shares Daunorubicin, Cytarabine, Leukaemia (all types) and the tag pipeline.
Shares Daunorubicin, Cytarabine and the tag pipeline.